Overview

Angiotensin Converting Enzyme (ACE) Inhibitors Market is poised to value over USD 12.4 billion by 2027 end.

FutureWise Market Research has instantiated a report that provides an intricate analysis of Angiotensin Converting Enzyme (ACE) Inhibitors Market trends that shall affect the overall market growth. Furthermore, it includes detailed information on the graph of profitability, SWOT analysis, market share and regional proliferation of this business. Moreover, the report offers insights on the current stature of prominent market players in the competitive landscape analysis of this market.

According to the research study conducted by FutureWise research analysts, the Angiotensin Converting Enzyme (ACE) Inhibitors Market is anticipated to attain substantial growth by the end of the forecast period. The report explains that this business is predicted to register a noteworthy growth rate over the forecast period. This report provides crucial information pertaining to the total valuation that is presently held by this industry and it also lists the segmentation of the market along with the growth opportunities present across this business vertical.

Major players included in the Angiotensin Converting Enzyme (ACE) Inhibitors Market:
• Abbott
• Bausch Health Companies Inc.
• AbbVie Inc.
• Pfizer Inc.
• DAIICHI SANKYO COMPANY, LIMITED
• Novartis AG
• Merck KGaA
• La Jolla Pharmaceutical Company
• Quantum Genomics
• AstraZeneca
• Johnson & Johnson Services, Inc.
• Eli Lilly and Company
• Par Pharmaceutical
• Sanofi
• Bristol-Myers Squibb Company
• Sandoz AG
• Mayo Foundation for Medical Education and Research (MFMER)
• Bayer AG
• Takeda Pharmaceutical Company Limited
• GlaxoSmithKline plc
• Teva Pharmaceutical Industries Ltd.
 (Note: The list of the major players will be updated with the latest market scenario and trends)

Angiotensin Converting Enzyme (ACE) Inhibitors Market Segmentation:
By Drug
• Lisinopril
• Ramipril
• Enalapril
• Benazepril
• Fosinopril
• Captopril
• Moexipril
• Others

By Application
• Heart Failure
• Hypertension
• Diabetes
• Heart Attack
• Chronic Kidney Disease
• Others

By Distribution Channel
• Retail Pharmacy
• Hospital Pharmacy
• E-Commerce Websites
• Online Drug Stores

By Region
• North America
• Europe
• Asia-Pacific
• Latin America
• Middle East and Africa

Competitive Landscape:
• Tier 1 players- established companies in the market with a major market share
• Tier 2 players
• Emerging players which are growing rapidly
• New Entrants

FutureWise Key Takeaways:
• Growth prospects
• SWOT analysis
• Key trends
• Key data-points affecting market growth

Objectives of the Study:
• To provide with an exhaustive analysis on the Angiotensin Converting Enzyme (ACE) Inhibitors Market By Drug, By Application, By Distribution Channel and By Region.
• To cater comprehensive information on factors impacting market growth (drivers, restraints, opportunities, and industry-specific restraints)
• To evaluate and forecast micro-markets and the overall market
• To predict the market size, in key regions— North America, Europe, Asia Pacific, Latin America and Middle East and Africa.
• To record and evaluate competitive landscape mapping- product launches, technological advancements, mergers and expansions

Flexible Delivery Model:
• We have a flexible delivery model and you can suggest changes in the scope/table of content as per your requirement
• The customization Mobility Care offered are free of charge with purchase of any license of the report
• You can directly share your requirements/changes to the current table of content to: sales@futurewiseresearch.com

Table of Contents

1. Market Introduction
  1.1 Objectives of the Study
  1.2 Market Definition
  1.3 Market Scope
      1.3.1 Years Considered for the Study
      1.3.2 Market Covered
  1.4 Currency
  1.5 Limitations
  1.6 Stakeholders

2. Research Methodology
   2.1 Research Data
       2.1.1 Secondary Data
             2.1.1.1 Key Data from Secondary Sources
       2.1.2 Primary Data
             2.1.2.1 Key Data from Primary Sources
   2.2 Market Size Estimation
   2.3 Market Breakdown and Data Triangulation
   2.4 Assumptions for the Study  

3. Executive Summary
  3.1 Market Outlook
  3.2 Segment Outlook
  3.3 Competitive Insights

4. Global Angiotensin Converting Enzyme (ACE) Inhibitors Market Variables, Trends & Scope
  4.1. Market Lineage Outlook
  4.2. Penetration and Growth Prospect Mapping
  4.3. Industry Value Chain Analysis
  4.4. Cost Analysis Breakdown
  4.5. Technology Overview
  4.6. Regulatory Framework
       4.6.1. Reimbursement Framework
       4.6.2. Standards and Compliances

5. Market Overview
  5.1. Market Dynamics
       5.1.1. Market Driver Analysis
              5.1.1.1. Increasing focus of Angiotensin Converting Enzyme (ACE) Inhibitors Companies on Brand Protection
              5.1.1.2. Untapped Opportunities in Emerging Regions
       5.1.2. Market Restraint Analysis
              5.1.2.1. High Cost Associated with Implementation of Predictive Analysis
       5.1.3. Industry Challenges
              5.1.3.1. Presence of Ambiguous Regulatory Framework

6. Global Angiotensin Converting Enzyme (ACE) Inhibitors Market Analysis Tools
  6.1. Industry Analysis - Porter’s
       6.1.1. Supplier Power
       6.1.2. Buyer Power
       6.1.3. Substitution Threat
       6.1.4. Threat from New Entrants
       6.1.5. Competitive Rivalry
  6.2. Pestel Analysis
       6.2.1. Political Landscape
       6.2.2. Environmental Landscape
       6.2.3. Social Landscape
       6.2.4. Technology Landscape
       6.2.5. Legal Landscape
  6.3. Major Deals And Strategic Alliances Analysis
       6.3.1. Joint Ventures
       6.3.2. Mergers and Acquisitions
       6.3.3. Licensing and Partnership
       6.3.4. Technology Collaborations
       6.3.5. Strategic Divestments
  6.4. Market Entry Strategies
  6.5. Case Studies

7. Global Angiotensin Converting Enzyme (ACE) Inhibitors Market, By Drug Historical Analysis and Forecast 2020-2027 (USD Million)
  7.1. Lisinopril
  7.2. Ramipril
  7.3. Enalapril
  7.4. Benazepril
  7.5. Fosinopril
  7.6. Captopril
  7.7. Moexipril
  7.8. Others

8. Global Angiotensin Converting Enzyme (ACE) Inhibitors Market, By Application Historical Analysis and Forecast 2020-2027 (USD Million)
  8.1. Heart Failure
  8.2. Hypertension
  8.3. Diabetes
  8.4. Heart Attack
  8.5. Chronic Kidney Disease
  8.6. Others

9. Global Angiotensin Converting Enzyme (ACE) Inhibitors Market, By Distribution Channel Historical Analysis and Forecast 2020-2027 (USD Million)
  9.1. Retail Pharmacy
  9.2. Hospital Pharmacy
  9.3. E-Commerce Websites
  9.4. Online Drug Stores

10. North America Angiotensin Converting Enzyme (ACE) Inhibitors Market Analysis 2015–2019 and Forecast 2020–2027 (USD Million)
  10.1. Introduction
  10.2. Historical Market Size (USD Million) Analysis By Country, 2015-2019
       10.2.1. U.S.A
       10.2.2. Canada
       10.2.3. Mexico
  10.3. Market Size (USD Million) Forecast for North America 2020-2027

11. Latin America Angiotensin Converting Enzyme (ACE) Inhibitors Market Analysis 2015–2019 and Forecast 2020–2027 (USD Million)
   11.1. Introduction
   11.2. Historical Market Size (USD Million) Analysis By Country, 2015-2019
         11.2.1. Brazil
         11.2.2. Venezuela
         11.2.3. Argentina
         11.2.4. Rest of Latin America
   11.3. Market Size (USD Million) Forecast for Latin America 2020-2027

12. Europe Angiotensin Converting Enzyme (ACE) Inhibitors Market Analysis 2015–2019 and Forecast 2020–2027 (USD Million)
   12.1. Introduction
   12.2. Historical Market Size (USD Million) Analysis By Country, 2015-2019
         12.2.1. Germany
         12.2.2. U.K        
         12.2.3. France
         12.2.4. Italy
         12.2.5. Spain
         12.2.6. Russia
         12.2.7. Poland
         12.2.8. Rest of Europe
   12.3. Market Size (USD Million) Forecast for Europe 2020-2027

13. Asia Pacific Angiotensin Converting Enzyme (ACE) Inhibitors Market Analysis 2015–2019 and Forecast 2020–2027 (USD Million)
   13.1. Introduction
   13.2. Historical Market Size (USD Million) Analysis By Country, 2015-2019
         13.2.1. Japan
         13.2.2. China
         13.2.3. India
         13.2.4. Australia and New Zealand
         13.2.5. ASEAN
         13.2.6. Rest of Asia Pacific
   13.3. Market Size (USD Million) Forecast for Asia Pacific 2020-2027  

14. Middle East and Africa Market Analysis 2015–2019 and Forecast 2020–2027 (USD Million)
   14.1. Introduction
   14.2. Historical Market Size (USD Million) Analysis By Country, 2015-2019
         14.2.1. Saudi Arabia
         14.2.2. UAE
         14.2.3. South Africa
         14.2.4. Egypt
   14.3. Market Size (USD Million) Forecast for MEA 2020-2027

15. Market Share Analysis and Competitive Landscape  
   15.1. Global Landscape - Key Players, Revenue and Presence
   15.2. Global Share Analysis - Key Players (Tier 1, Tier 2, Tier 3)
   15.3. Global Emerging Companies
   15.4. North America - Market Share Analysis and Key Regional Players
   15.5. Europe - Market Share Analysis and Key Regional Players
   15.6. Asia Pacific - Market Share Analysis and Key Regional Players
   15.7. Global Key Player - Growth Matrix

16. Company Profiles (Competition Dashboard, Competitors Deep Dive, Products Offered and Financial Layouts)
   16.1. Abbott
         16.1.1. Company Overview
         16.1.2. Product Portfolio
         16.1.3. SWOT Analysis
         16.1.4. Financial Overview
         16.1.5. Strategic Overview
   16.2. Bausch Health Companies Inc.
         16.2.1. Company Overview
         16.2.2. Product Portfolio
         16.2.3. SWOT Analysis
         16.2.4. Financial Overview
         16.2.5. Strategic Overview
   16.3. AbbVie Inc.
         16.3.1. Company Overview
         16.3.2. Product Portfolio
         16.3.3. SWOT Analysis
         16.3.4. Financial Overview
         16.3.5. Strategic Overview
   16.4. Pfizer Inc.
         16.4.1. Company Overview
         16.4.2. Product Portfolio
         16.4.3. SWOT Analysis
         16.4.4. Financial Overview
         16.4.5. Strategic Overview
   16.5. DAIICHI SANKYO COMPANY, LIMITED
         16.5.1. Company Overview
         16.5.2. Product Portfolio
         16.5.3. SWOT Analysis
         16.5.4. Financial Overview
         16.5.5. Strategic Overview          
   16.6. Novartis AG
         16.6.1. Company Overview
         16.6.2. Product Portfolio
         16.6.3. SWOT Analysis
         16.6.4. Financial Overview
         16.6.5. Strategic Overview      
   16.7. Merck KGaA
         16.7.1. Company Overview
         16.7.2. Product Portfolio
         16.7.3. SWOT Analysis
         16.7.4. Financial Overview
         16.7.5. Strategic Overview
   16.8. La Jolla Pharmaceutical Company
         16.8.1. Company Overview
         16.8.2. Product Portfolio
         16.8.3. SWOT Analysis
         16.8.4. Financial Overview
         16.8.5. Strategic Overview
   16.9. Quantum Genomics
         16.9.1. Company Overview
         16.9.2. Product Portfolio
         16.9.3. SWOT Analysis
         16.9.4. Financial Overview
         16.9.5. Strategic Overview
   16.10.AstraZeneca
         16.10.1. Company Overview
         16.10.2. Product Portfolio
         16.10.3. SWOT Analysis
         16.10.4. Financial Overview
         16.10.5. Strategic Overview
   16.11.Johnson & Johnson Services, Inc.
         16.11.1. Company Overview
         16.11.2. Product Portfolio
         16.11.3. SWOT Analysis
         16.11.4. Financial Overview
         16.11.5. Strategic Overview
   16.12.Eli Lilly and Company
         16.12.1. Company Overview
         16.12.2. Product Portfolio
         16.12.3. SWOT Analysis
         16.12.4. Financial Overview
         16.12.5. Strategic Overview
   16.13.Par Pharmaceutical
         16.13.1. Company Overview
         16.13.2. Product Portfolio
         16.13.3. SWOT Analysis
         16.13.4. Financial Overview
         16.13.5. Strategic Overview
   16.14.Sanofi
         16.14.1. Company Overview
         16.14.2. Product Portfolio
         16.14.3. SWOT Analysis
         16.14.4. Financial Overview
         16.14.5. Strategic Overview
   16.15.Bristol-Myers Squibb Company
         16.15.1. Company Overview
         16.15.2. Product Portfolio
         16.15.3. SWOT Analysis
         16.15.4. Financial Overview
         16.15.5. Strategic Overview          
   16.16.Sandoz AG
         16.16.1. Company Overview
         16.16.2. Product Portfolio
         16.16.3. SWOT Analysis
         16.16.4. Financial Overview
         16.16.5. Strategic Overview      
   16.17.Mayo Foundation for Medical Education and Research (MFMER)
         16.17.1. Company Overview
         16.17.2. Product Portfolio
         16.17.3. SWOT Analysis
         16.17.4. Financial Overview
         16.17.5. Strategic Overview
   16.18.Bayer AG
         16.18.1. Company Overview
         16.18.2. Product Portfolio
         16.18.3. SWOT Analysis
         16.18.4. Financial Overview
         16.18.5. Strategic Overview
   16.19.Takeda Pharmaceutical Company Limited
         16.19.1. Company Overview
         16.19.2. Product Portfolio
         16.19.3. SWOT Analysis
         16.19.4. Financial Overview
         16.19.5. Strategic Overview
   16.20.GlaxoSmithKline plc
         16.20.1. Company Overview
         16.20.2. Product Portfolio
         16.20.3. SWOT Analysis
         16.20.4. Financial Overview
         16.20.5. Strategic Overview
   16.21.Teva Pharmaceutical Industries Ltd.
         16.21.1. Company Overview
         16.21.2. Product Portfolio
         16.21.3. SWOT Analysis
         16.21.4. Financial Overview
         16.21.5. Strategic Overview          

17. Pre and Post COVID-19 Impact
   17.1. Positive influence on the healthcare industry
   17.2. The financial disruption of the manufacturing sector
   17.3. Impact of COVID-19 on emerging companies
   17.4. Significant mandates in the healthcare regulations initiated by administrations
   17.5. The overall economic slowdown of the developing and developed nations

18. FutureWise SME Key Takeaway Points for Client

Tables

Figures